Brought to you by:
Abbott’s Esprit BTK scaffold system given US FDA approval for CLTI treatment
Abbott has announced that the US Food and Drug Administration (FDA) has approved the Esprit BTK everolimus-eluting resorbable scaffold system (Esprit BTK system), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is…
Interim analysis provides early window into real-world Alto stent graft outcomes
In a podium-first presentation on the final day of the 2024 Charing Cross (CX) International Symposium (23–25 April, London, UK), Sean Lyden (Cleveland Clinic, Cleveland, USA) disclosed an interim analysis from the JAGUAR trial and, in doing so, gave delegates…
Questions linger: BASIL-3 does not find for drug-eluting technologies for CLTI
In the UK National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA)-funded BASIL-3 randomised controlled trial (RCT), neither drug-coated balloon (DCB) angioplasty with or without bare metal stent nor drug-eluting stent (DES), when used in the femoropopliteal…
Prosthetic valve implantation shows “vast” improvements in deep chronic venous insufficiency
“The surgical challenges of repairing deep venous reflux have been present for more than a generation. It is worth reflecting on the fact that this new technology has made the majority of patients vastly better,” were the words of principal…
Penumbra announces FDA clearance of Lightning Flash 2 for the treatment of PE
Penumbra has announced the US Food and Drug Administration (FDA) clearance and launch of Lightning Flash 2, the next generation computer assisted vacuum thrombectomy (CAVT) system to remove venous thrombus and treat pulmonary embolism (PE), a press release states. Lightning Flash…
CX united: Vascular world set to converge with challenging cases
The World Federation of Vascular Societies (WFVS) is bringing the vascular world together at CX 2024 to chew over both challenging cases and leadership challenges. The pair of sessions is part of the legacy left by Professor Roger M. Greenhalgh,…
Paclitaxel controversy: Yes, device restrictions did cause harm
“Unfortunately, we are doing worse for our patients today,” were the sobering thoughts of Eric Secemsky (Boston, United States) during a late-breaking presentation in this morning’s Peripheral Arterial Controversies programme. Among several presentations on paclitaxel safety, he reported that: yes,…
SVS launches Vascular Board Certification Model Task Force
The Society for Vascular Surgery (SVS) Executive Board has established the Vascular Board Certification Model Task Force to deliver a final report entitled “Free-standing or federated Board certification: An analysis of the optimal path forward for vascular surgery” by the…
SVS announces candidates for 2024–25 vice president
The Society for Vascular Surgery (SVS) has announced Linda Harris, MD, and Palma Shaw, MD, as the candidates for the upcoming election for SVS vice president. “This is an exciting year,” said SVS Nominating Committee Chair Ronald Dalman, MD, who…
Latest iteration of SVS program seeks to help foster development of resilient leaders
As the Society for Vascular Surgery (SVS) prepares to launch its fifth cohort of the Leadership Development Program (LDP), anticipation is high among aspiring leaders in vascular surgery. This seven-month-long program has become a cornerstone for over 100 members of…